Colon cancer treatment is personalized based on stage, overall health and tumor characteristics. Early detection and accurate ...

Haystack MRD test detects minimal residual disease in stage 2 colorectal cancer patients post-surgery, using circulating tumor DNA (ctDNA) for less invasive monitoring. The FDA's breakthrough device ...

Circulating tumor DNA (ctDNA)—genetic material shed from tumors into the bloodstream—may help risk-stratify patients with Stage 3 colon cancer by tailoring chemotherapy options after surgery based on ...

While there are several treatment options for colon cancer, not all of them work for all cancer types. Deficient mismatch repair (dMMR) colon cancer is known to be less responsive to chemotherapy than ...

Circulating tumor DNA (ctDNA) — genetic material shed from tumors into the bloodstream — may help risk-stratify patients with Stage 3 colon cancer by tailoring chemotherapy options after surgery based ...

Meta analysis in obese colorectal cancer patients found robotic assisted surgery modestly reduced hospital stay versus ...